|
| 36202685 | Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau's Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50. | Eur Urol | 2023 |
| 37446306 | A C57BL/6J Fancg-KO Mouse Model Generated by CRISPR/Cas9 Partially Captures the Human Phenotype. | Int J Mol Sci | 2023 |
| 36972661 | Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. | Eur J Cancer | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36966502 | Molecular testing of DNA damage response pathways in prostate cancer patients. | Curr Opin Oncol | 2023 |
| 37030500 | Mismatch repair protein status of non-neoplastic uterine and intestinal mucosa in patients with Lynch syndrome and double somatic mismatch repair protein mutations. | Hum Pathol | 2023 |
| 37196219 | MLH1 Loss in Primary Prostate Cancer. | JCO Precis Oncol | 2023 |
| 36779357 | Clinical, pathologic, and molecular features of amphicrine prostate cancer. | Prostate | 2023 |
| 36399432 | Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. | Cancer Discov | 2023 |
| 36681683 | Inhibition of carnitine palmitoyl-transferase 1 is a potential target in a mouse model of Parkinson's disease. | NPJ Parkinsons Dis | 2023 |
| 36905927 | A Lamb1Dendra2 mouse model identifies basement-membrane-producing origins and dynamics in PyMT breast tumors. | Dev Cell | 2023 |
| 36669105 | Mammalian life depends on two distinct pathways of DNA damage tolerance. | Proc Natl Acad Sci U S A | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34363009 | PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35834759 | <i>BRCA2</i> Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. | JCO Precis Oncol | 2022 |
| 35467778 | Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. | Cancer Med | 2022 |
| 35819193 | Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine. | Nucleic Acids Res | 2022 |
| 35688932 | HideRNAs protect against CRISPR-Cas9 re-cutting after successful single base-pair gene editing. | Sci Rep | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35483878 | The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the <i>PIK3CA</i>-related megalencephaly-capillary malformation (MCAP) syndrome: a case report. | Cold Spring Harb Mol Case Stud | 2022 |
| 35355055 | Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care. | Brain | 2022 |
| 36467895 | Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy. | Cancer Res Commun | 2022 |
| 36337169 | Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations. | Cancer Res Commun | 2022 |
| 35929009 | Ordering and Interpreting Precision Oncology Studies for Adults With Advanced Solid Tumors: A Primer. | Fed Pract | 2022 |
| 36124727 | KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas. | Oncologist | 2022 |
| 36089135 | The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. | Ann Oncol | 2022 |
| 36344179 | Molecular Genetics of Prostate Cancer and Role of Genomic Testing. | Surg Pathol Clin | 2022 |
| 33837488 | A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer. | Fam Cancer | 2022 |
| 35294224 | Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer. | JCO Precis Oncol | 2022 |
| 35020836 | Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. | Blood | 2022 |
| 34863587 | Inherited TP53 Variants and Risk of Prostate Cancer. | Eur Urol | 2022 |
| 33151258 | Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. | JAMA Oncol | 2021 |
| 33626496 | Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. | Eur J Cancer | 2021 |
| 33931719 | Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS. | Commun Biol | 2021 |
| 34877933 | Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. | JCI Insight | 2021 |
| 34548335 | A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair. | Cancer Res | 2021 |
| 34580112 | Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. | Clin Cancer Res | 2021 |
| 34250417 | Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. | JCO Precis Oncol | 2021 |
| 34171218 | The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. | Can Urol Assoc J | 2021 |
| 34086042 | Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. | JAMA Oncol | 2021 |
| 33398501 | [Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference]. | Pathologe | 2021 |
| 33215787 | Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. | Oncologist | 2021 |
| 33393477 | Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. | Gynecol Oncol | 2021 |
| 32453797 | Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. | PLoS One | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31783044 | MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative sequencing from different tumor areas. | Hum Pathol | 2020 |
| 32044806 | Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. | Am J Surg Pathol | 2020 |
| 31883735 | Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. | Gynecol Oncol | 2020 |
| 31911673 | Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots". | Genet Med | 2020 |